, Volume 47, Issue 1, pp 107–113 | Cite as

Empiric therapy for kidney stones

  • David S. GoldfarbEmail author
Invited Review


Careful phenotyping of patients to classify those with kidney stones has a long and important history in revealing the chemical basis for stone formation. Advances in our genetic understanding of kidney stones will lead to incredible insights regarding the pathophysiology of this common disorder. At this time, both evaluation of urine chemistry and genotyping of patients are extremely useful in the setting of a university and research-based kidney stone clinic. For much of the world, in a more clinically focused setting, these techniques are neither available nor absolutely necessary. Careful implementation of an empiric prescription based on stone composition would have an important effect to reduce stone recurrence in the world’s many stone formers. Increased fluid intake, generic dietary manipulations, and prescription of potassium citrate and thiazides are all appropriate empiric therapies for people with calcium and uric acid kidney stones.


Diet Genetics Kidney calculi Nephrolithiasis Potassium citrate Thiazides Uric acid Urolithiasis 



The author appreciates the support of The Rare Kidney Stone Consortium (U54DK083908-01), part of Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS and NIDDK. This consortium is funded through collaboration between NCATS and the NIDDK.

Compliance with ethical standards

Conflict of interest

Goldfarb: consultant: Alnylam, Retrophin; funding from NIDDK, NCATS.


  1. 1.
    Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Anglani F, Milliner DS, Palsson R (2013) Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol 28(10):1923–1942Google Scholar
  2. 2.
    Goldfarb DS, Fischer ME, Keich Y, Goldberg J (2005) A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 67(3):1053–1061Google Scholar
  3. 3.
    Milose JC, Kaufman SR, Hollenbeck BK, Wolf JS Jr, Hollingsworth JM (2014) Prevalence of 24-hour urine collection in high risk stone formers. J Urol 191(2):376–380Google Scholar
  4. 4.
    Pak CY, Britton F, Peterson R, Ward D, Northcutt C, Breslau NA, McGuire J, Sakhaee K, Bush S, Nicar M, Norman DA, Peters P (1980) Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med 69(1):19–30Google Scholar
  5. 5.
    Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR, American Urological A (2014) Medical management of kidney stones: AUA guideline. J Urol 192(2):316–324Google Scholar
  6. 6.
    Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petrik A, Turk C (2015) Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol 67(4):750–763Google Scholar
  7. 7.
    Goldfarb DS (2013) Kidney stones and the risk of coronary heart disease. Am J Kidney Dis 62(6):1039–1041Google Scholar
  8. 8.
    Rule AD, Lieske JC, Li X, Melton LJ 3rd, Krambeck AE, Bergstralh EJ (2014) The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol 25(12):2878–2886Google Scholar
  9. 9.
    Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ (1998) Body size and risk of kidney stones. J Am Soc Nephrol 9(9):1645–1652Google Scholar
  10. 10.
    Taylor EN, Stampfer MJ, Curhan GC (2005) Obesity, weight gain, and the risk of kidney stones. JAMA 293(4):455–462Google Scholar
  11. 11.
    Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky D, Curhan GC, Ferraro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, Lieske J, Marangella M, Milliner D, Preminger GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, Williams JC, Consensus Conference Group (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29(6):715–734Google Scholar
  12. 12.
    Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A (1996) Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 155(3):839–843Google Scholar
  13. 13.
    Xu C, Zhang C, Wang XL, Liu TZ, Zeng XT, Li S, Duan XW (2015) Self-fluid management in prevention of kidney stones: A PRISMA-compliant systematic review and dose-response meta-analysis of observational studies. Medicine (Baltimore) 94(27):e1042Google Scholar
  14. 14.
    Mass AY, Goldfarb DS, Shah O (2014) Taxi cab syndrome: a review of the extensive genitourinary pathology experienced by taxi cab drivers and what we can do to help. Rev Urol 16(3):99–104Google Scholar
  15. 15.
    Kim CW, Chang Y, Zhao D, Cainzos-Achirica M, Ryu S, Jung HS, Yun KE, Choi Y, Ahn J, Zhang Y, Rampal S, Baek Y, Lima JA, Shin H, Guallar E, Cho J, Sung E (2015) Sleep duration, sleep quality, and markers of subclinical arterial disease in healthy men and women. Arterioscler Thromb Vasc Biol 35(10):2238–2245Google Scholar
  16. 16.
    Policastro LJ, Saggi SJ, Goldfarb DS, Weiss JP (2017) Personalized intervention in monogenic stone formers. J Urol. Google Scholar
  17. 17.
    Ljunghall S, Danielson BG, Fellstrom B, Holmgren K, Johansson G, Wikstrom B (1985) Family history of renal stones in recurrent stone patients. Br J Urol 57(4):370–374Google Scholar
  18. 18.
    Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1997) Family history and risk of kidney stones. J Am Soc Nephrol 8(10):1568–1573Google Scholar
  19. 19.
    Vezzoli G, Soldati L, Gambaro G (2008) Update on primary hypercalciuria from a genetic perspective. JUrol 179(5):1676–1682Google Scholar
  20. 20.
    Oddsson A, Sulem P, Helgason H, Edvardsson VO, Thorleifsson G, Sveinbjornsson G, Haraldsdottir E, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Masson G, Holm H, Gudbjartsson DF, Thorsteinsdottir U, Indridason OS, Palsson R, Stefansson K (2015) Common and rare variants associated with kidney stones and biochemical traits. Nat Commun 6:7975Google Scholar
  21. 21.
    Vezzoli G, Terranegra A, Arcidiacono T, Soldati L (2011) Genetics and calcium nephrolithiasis. Kidney Int 80(6):587–593Google Scholar
  22. 22.
    Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, Spaneas L, Porath JD, Braun DA, Wassner AJ, Nelson CP, Tasic V, Sayer JA, Hildebrandt F (2015) Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26(3):543–551Google Scholar
  23. 23.
    Braun DA, Lawson JA, Gee HY, Halbritter J, Shril S, Tan W, Stein D, Wassner AJ, Ferguson MA, Gucev Z, Fisher B, Spaneas L, Varner J, Sayer JA, Milosevic D, Baum M, Tasic V, Hildebrandt F (2016) Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin J Am Soc Nephrol 11(4):664–672Google Scholar
  24. 24.
    Martin-Higueras C, Torres A, Salido E (2017) Molecular therapy of primary hyperoxaluria. J Inherit Metab Dis 40(4):481–489Google Scholar
  25. 25.
    Dindo M, Conter C, Oppici E, Ceccarelli V, Marinucci L, Cellini B (2018) Molecular basis of primary hyperoxaluria: clues to innovative treatments. Urolithiasis. Google Scholar
  26. 26.
    Chillaron J, Font-Llitjos M, Fort J, Zorzano A, Goldfarb DS, Nunes V, Palacin M (2010) Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 6(7):424–434Google Scholar
  27. 27.
    Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D, group VXs (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2(7):527–538Google Scholar
  28. 28.
    Hsi RS, Sanford T, Goldfarb DS, Stoller ML (2017) The role of the 24-hour urine collection in the prevention of kidney stone recurrence. J Urol 197(4):1084–1089Google Scholar
  29. 29.
    Parks JH, Coward M, Coe FL (1997) Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 51(3):894–900Google Scholar
  30. 30.
    Kocvara R, Plasgura P, Petrik A, Louzensky G, Bartonickova K, Dvoracek J (1999) A prospective study of nonmedical prophylaxis after a first kidney stone. BJU Int 84(4):393–398Google Scholar
  31. 31.
    Lingeman J, Mardis H, Kahnoski R, Goldfarb DS, Lacy S, Grasso M, Scheinman SJ, Parks JH, Asplin JR, Coe FL (1998) Medical reduction of stone risk in a network of treatment centers compared to a research clinic. J Urol 160(5):1629–1634Google Scholar
  32. 32.
    Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59(6):2290–2298Google Scholar
  33. 33.
    Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A (2002) Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346(2):77–84Google Scholar
  34. 34.
    Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1993) A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328(12):833–838Google Scholar
  35. 35.
    Taylor EN, Curhan GC (2008) Determinants of 24-hour urinary oxalate excretion. Clin J Am Soc Nephrol 3(5):1453–1460Google Scholar
  36. 36.
    Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N (1997) A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336(16):1117–1124Google Scholar
  37. 37.
    Taylor EN, Fung TT, Curhan GC (2009) DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 20(10):2253–2259Google Scholar
  38. 38.
    Taylor EN, Stampfer MJ, Mount DB, Curhan GC (2010) DASH-style diet and 24-hour urine composition. Clin J Amer Soc Nephrol 5(12):2315–2322Google Scholar
  39. 39.
    Goldfarb DS (2012) A woman with recurrent calcium phosphate kidney stones. Clin J Am Soc Nephrol 7(7):1172–1178Google Scholar
  40. 40.
    Asplin JR, Bauer KA, Kinder J, Muller G, Coe BJ, Parks JH, Coe FL (2003) Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 63(2):662–669Google Scholar
  41. 41.
    Jehle S, Hulter HN, Krapf R (2012) Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 98(1):207–217Google Scholar
  42. 42.
    Huen SC, Goldfarb DS (2007) Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis. J Urol 177(4):1238–1243Google Scholar
  43. 43.
    Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13(9):679–685Google Scholar
  44. 44.
    Wasnich R, Davis J, Ross P, Vogel J (1990) Effect of thiazide on rates of bone mineral loss: a longitudinal study. BMJ 301(6764):1303–1305Google Scholar
  45. 45.
    Wright JT Jr, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, Einhorn PT, Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR, Alderman MH, Group ACR (2009) ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 169(9):832–842Google Scholar
  46. 46.
    Obligado SH, Goldfarb DS (2008) The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 21(3):257–264Google Scholar
  47. 47.
    Ticinesi A, Guerra A, Allegri F, Nouvenne A, Cervellin G, Maggio M, Lauretani F, Borghi L, Meschi T (2018) Determinants of calcium and oxalate excretion in subjects with calcium nephrolithiasis: the role of metabolic syndrome traits. J Nephrol 31(3):395–403Google Scholar
  48. 48.
    Nicar MJ, Peterson R, Pak CY (1984) Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol 131(3):430–433Google Scholar
  49. 49.
    Arrabal-Polo MA, Arias-Santiago S, de Haro-Munoz T, Lopez-Ruiz A, Orgaz-Molina J, Gonzalez-Torres S, Zuluaga-Gomez A, Arrabal-Martin M (2013) Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. Urology 81(4):731–737Google Scholar
  50. 50.
    Prochaska M, Taylor E, Vaidya A, Curhan G (2017) Low bone density and bisphosphonate use and the risk of kidney stones. Clin J Am Soc Nephrol 12(8):1284–1290Google Scholar
  51. 51.
    Trinchieri A, Montanari E (2017) Prevalence of renal uric acid stones in the adult. Urolithiasis 45(6):553–562Google Scholar
  52. 52.
    Mehta TH, Goldfarb DS (2012) Uric acid stones and hyperuricosuria. Adv Chronic Kidney Dis 19(6):413–418Google Scholar
  53. 53.
    Maalouf NM, Cameron MA, Moe OW, Sakhaee K (2004) Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 13(2):181–189Google Scholar
  54. 54.
    Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K (2004) The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65(2):386–392Google Scholar
  55. 55.
    Ware EB, Riehle E, Smith JA, Zhao W, Turner ST, Kardia SL, Lieske JC (2015) SLC2A9 genotype is associated with SLC2A9 gene expression and urinary uric acid concentration. PLoS One 10(7):e0128593Google Scholar
  56. 56.
    Canales BK, Smith JA, Weiner ID, Ware EB, Zhao W, Kardia SLR, Curhan GC, Turner ST, Perinpam M, Lieske JC (2017) Polymorphisms in renal ammonia metabolism genes correlate with 24-hour urine pH. Kidney Int Rep 2(6):1111–1121Google Scholar
  57. 57.
    Rodman JS (2002) Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology 60(3):378–382Google Scholar

Copyright information

© This is a U.S. government work and its text is not subject to copyright protection in the United States; however, its text may be subject to foreign copyright protection 2018

Authors and Affiliations

  1. 1.Nephrology DivisionNYU Langone HealthNew YorkUSA
  2. 2.NYU School of MedicineNew YorkUSA

Personalised recommendations